42411-95-0

Basic information

• Product Name: 3-NITRO-4-PROPYLANILINE
• Synonyms: 3-NITRO-4-PROPYLANILINE
• CAS NO: 42411-95-0
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Mol File: 42411-95-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-NITRO-4-PROPYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-NITRO-4-PROPYLANILINE(42411-95-0)
• EPA Substance Registry System: 3-NITRO-4-PROPYLANILINE(42411-95-0)

Safety Data

• Hazardous Substances Data: 42411-95-0(Hazardous Substances Data)

Upstream product

• 7783-06-4 hydrogen sulfide 
• 2696-84-6 4-propylaniline 
• 103-65-1 phenylpropane 
• 7664-93-9 sulfuric acid 
• 24503-35-3 2,4-dinitro-1-propylbenzene 
• 7697-37-2 nitric acid 

Downstream Products

• 90942-41-9 2-Propyl-5-chlor-1-nitro-benzol 
• 3355-08-6 4-Bromo-2-nitro-1-propyl-benzene 
• 698392-87-9 3-Amino-4-propyl-phenol 
• 859943-94-5 1,2-dinitro-3-propyl-benzene 
• 860735-42-8 2,3-dinitro-4-propyl-aniline 
• 860745-40-0 acetic acid-(2,3-dinitro-4-propyl-anilide) 
• 27581-20-0 2-n-propyl-5-chlorophenol 
• 56152-26-2 5-Brom-2-propyl-phenol 
• 90415-69-3 5-chloro-2-propylphenylamine 
• 3355-21-3 5-Bromo-2-propyl-phenylamine 
• 93897-53-1 <5-Chlor-2-propyl-phenyl>-4-brom-benzolsulfonat 
• 92425-68-8 <5-Brom-2-propyl-phenyl>-4-brom-benzolsulfonat 
• 873056-00-9 (3-nitro-4-propylphenyl)carbamic acid tert-butyl ester 
• 873056-02-1 (3-amino-4-propylphenyl)-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH

Provided herein are Pyrazole Pyrazine Amine Compounds having the following structure:Formula (I). Wherein Q and R1-R3 are as defined herein, compositions comprising an effective amount of a Pyrazole Pyrazine Amine Compound and methods for treating or preventing inflammatory conditions, immunological conditions, cancer, neurodegenerative diseases, age-related diseases, cardiovascular diseases and metabolic conditions, or conditions treatable or preventable by inhibition of an IKK, or an IKK pathway, comprising administering an effective amount of a Pyrazole Pyrazine Amine Compound to a patient in need thereof.